紫杉醇联合洛铂在局部晚期宫颈癌(LACC)患者术前新辅助化疗中的效果分析

Analysis of the Efficacy of Paclitaxel Combined with Lobaplatin in Preoperative Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer(LACC)

目的研究局部晚期宫颈癌(LACC)患者术前开展紫杉醇、洛铂联合新辅助化疗的价值。方法纳入本院自2016年2月至2019年2月接收的局部晚期宫颈癌患者(n=60)作为研究对象,对所有患者开展宫颈癌根治术,并以随机平衡序贯法为基准,将患者分为试验组(n=30)、对照组(n=30)。对照组开展氟尿嘧啶、顺铂新辅助化疗治疗,试验组开展紫杉醇、洛铂新辅助化疗治疗。评估两组患者的临床总有效率、手术指标、不良反应发生率、肿瘤标志物水平。结果试验组临床总有效率(66.67%)高于对照组(23.33%),P<0.05。试验组手术指标优于对照组(P<0.05)。试验组不良反应发生率低于对照组(P<0.05)。试验组细胞角蛋白19片段(CYFRA21-1)、鳞状细胞癌相关抗原(SCCAg)低于对照组(P<0.05)。结论局部晚期宫颈癌(LACC)患者术前开展紫杉醇、洛铂联合新辅助化疗的价值显著,既可降低不良反应发生率,又可改善淋巴结转移情况。

Objective To study the value of paclitaxel and lobaplatin combined with neoadjuvant chemotherapy in patients with locally advanced cervical cancer(LACC).Methods The patients with locally advanced cervical cancer(n=60)who were accepted by our hospital from February 2016 to February 2019 were included as the research object.All patients were treated with radical resection of cervical cancer.Divided into experimental group(n=30)and control group(n=30).The control group received neoadjuvant chemotherapy with fluorouracil and cisplatin,and the experimental group received neoadjuvant chemotherapy with paclitaxel and lobaplatin.To evaluate the total clinical effective rate,surgical indicators,incidence of side effects,and tumor marker levels of the two groups of patients.Results The total clinical effective rate of the experimental group was 66.67%higher than that of the control group(P<0.05).The operative indexes of the experimental group were better than those of the control group(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group(P<0.05).Cytokeratin 19 fragment(CYFRA21-1)and squamous cell carcinoma associated antigen(SCCAg)in the experimental group were lower than those in the control group(P<0.05).Conclusion Paclitaxel and lobaplatin combined with neoadjuvant chemotherapy have significant value in preoperative treatment of locally advanced cervical cancer(LACC)patients,which can reduce the incidence of adverse reactions and improve lymph node metastasis.